Commitments and contingencies (Additional Information) (Details) - shares |
Mar. 31, 2026 |
Dec. 31, 2025 |
Dec. 30, 2024 |
|---|---|---|---|
| Restructuring Cost and Reserve [Line Items] | |||
| Common stock, shares issued | 75,462,390 | 75,462,390 | |
| Nova Pharmaceuticals [Member] | |||
| Restructuring Cost and Reserve [Line Items] | |||
| Common stock, shares issued | 7,323 |
| X | ||||||||||
- Definition Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Details
|